Standard InChI: InChI=1S/C21H20O3/c1-22-19-13-16(14-20(23-2)21(19)24-3)9-8-15-10-11-17-6-4-5-7-18(17)12-15/h4-14H,1-3H3/b9-8-
Standard InChI Key: GOOTUFTVCKSZRA-HJWRWDBZSA-N
Associated Targets(Human)
A549 127892 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HT-29 80576 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
SK-MEL-28 48833 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HCT-116 91556 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HL-60 67320 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HeLa 62764 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HepG2 196354 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
HEK293 82097 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Associated Targets(non-human)
P388 20296 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Tubulin beta chain 424 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Transcription factor SOX-18 84 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: No
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Small molecule
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 320.39
Molecular Weight (Monoisotopic): 320.1412
AlogP: 5.04
#Rotatable Bonds: 5
Polar Surface Area: 27.69
Molecular Species: NEUTRAL
HBA: 3
HBD: 0
#RO5 Violations: 1
HBA (Lipinski): 3
HBD (Lipinski): 0
#RO5 Violations (Lipinski): 1
CX Acidic pKa:
CX Basic pKa:
CX LogP: 4.83
CX LogD: 4.83
Aromatic Rings: 3
Heavy Atoms: 24
QED Weighted: 0.62
Np Likeness Score: 0.18
References
1.Maya AB, del Rey B, Lamamie de Clairac RP, Caballero E, Barasoain I, Andreu JM, Medarde M.. (2000) Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4., 10 (22):[PMID:11086727][10.1016/s0960-894x(00)00506-0]
2.Pérez-Melero C, Maya AB, del Rey B, Peláez R, Caballero E, Medarde M.. (2004) A new family of quinoline and quinoxaline analogues of combretastatins., 14 (14):[PMID:15203159][10.1016/j.bmcl.2004.04.098]
3.Maya AB, Pérez-Melero C, Mateo C, Alonso D, Fernández JL, Gajate C, Mollinedo F, Peláez R, Caballero E, Medarde M.. (2005) Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety., 48 (2):[PMID:15658869][10.1021/jm0310737]
4.Alvarez C, Alvarez R, Corchete P, Pérez-Melero C, Peláez R, Medarde M.. (2007) Synthesis and biological activity of naphthalene analogues of phenstatins: naphthylphenstatins., 17 (12):[PMID:17434303][10.1016/j.bmcl.2007.03.082]
5.Mamidyala SK, Ramu S, Huang JX, Robertson AA, Cooper MA.. (2013) Efficient synthesis of anacardic acid analogues and their antibacterial activities., 23 (6):[PMID:23416004][10.1016/j.bmcl.2013.01.074]
6.Makar S, Saha T, Singh SK.. (2019) Naphthalene, a versatile platform in medicinal chemistry: Sky-high perspective., 161 [PMID:30366253][10.1016/j.ejmech.2018.10.018]
7. (2018) Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases,